Key Highlights
- Matthias Evers, Ph.D., appointed as an independent director at IMIDomics.
- Dr. Evers brings decades of expertise in life sciences, drug development, and biotech strategy.
- His experience aligns with IMIDomics’ data-driven approach to developing precision therapies.
Source: Business Wire
Notable Quotes
- “IMIDomics’ integration of multi-omics data with clinical insights presents a massive opportunity to accelerate the development of precision therapies.” — Dr. Matthias Evers, Independent Director at IMIDomics, Inc
- “His deep experience in fostering innovative partnerships and driving life sciences discoveries to the market aligns perfectly with our focus on advancing our pharmaceutical pipeline.” — Dr. Fred Craves, Chairman and CEO at IMIDomics
SoHC's Take
Dr. Evers’ appointment is a strategic move for IMIDomics as the company continues to advance its focus on immune-mediated inflammatory diseases (IMIDs). His global expertise in drug discovery, particularly with the integration of AI and PanOmics-driven approaches, will be a vital asset in accelerating IMIDomics’ precision medicine initiatives. This leadership addition reflects the company’s commitment to translating complex biological data into meaningful therapies, ultimately benefiting patients with limited or no treatment options.
Heading
Key Highlights Shore Capital Partners launches Agentis Longevity to lead the longevity healthcare sector. Jimmy St Louis named CEO, bringing expertise from Regenerative Medicine ...
Key Highlights Nymbl Systems announces strategic partnership with Frontier Growth to accelerate growth and innovation. Frontier Growth brings 25+ years of growth equity expertise to ...
Key Highlights Launch of fingertip blood collection technology using BD’s MiniDraw™ and Babson’s BetterWay for U.S. health systems. Revolutionizes access with fewer ...
Key Highlights Anatomy Financial raises $19M in Series A funding, led by Canapi Ventures. Neil Underwood (Canapi) and Nicole Quinn ...
Key Highlights Wendy Barnes to assume role as GoodRx CEO on January 1, 2025. Brings 30+ years of leadership in pharmacy and healthcare benefit industries. Former CEO of RxBenefits and President of Express ...
Key Highlights Mike Butler, former Providence president, joins Linus Health's board of directors. Butler brings decades of healthcare leadership and ...
